Experimental therapy targets neural repair to combat blindness from glaucoma and diabetic retinopathy LOS ANGELES — Spinogenix is spotlighting new preclinical findings that could reshape how vision-threatening diseases are treated, as its experimental drug tazbentetol (SPG302) demonstrates the ability to protect and restore retinal function. The results are being presented at the Association for Research …